Gynecologic Oncology

Gynecol Oncol · ISSN (print) 0090-8258 · ISSN (e) 1095-6859 · 303 papers in corpus
erratum 2026
doi:10.1016/j.ygyno.2026.05.029 ·PMID:42229041
article 2026
doi:10.1016/j.ygyno.2026.05.004 ·PMID:42119308

OBJECTIVE: To critically evaluate the evidence linking endometriosis to ovarian cancer, with particular focus on endometrioid and clear cell histologic subtypes, and to inform risk stratification and patient counseling. METHODS: A systemat…

2026
doi:10.1016/j.ygyno.2026.05.020 ·PMID:42217257

OBJECTIVE: To identify clinicopathologic predictors of concurrent endometrial carcinoma (EC) and need for lymph node assessment at time of hysterectomy for atypical endometrial hyperplasia (AEH) in a minority-enriched population. METHODS: …

2026
doi:10.1016/j.ygyno.2026.04.017 ·PMID:42102522

ObjectiveTo explore uptake of risk-reducing gynecologic surgery in a diverse patient population with Lynch syndrome.MethodsChart reviews of women with Lynch syndrome were conducted at a safety-net hospital and university medical center, inc…

article 2025
doi:10.1016/j.ygyno.2025.04.520
other 2025
doi:10.1016/j.ygyno.2025.02.017 ·PMID:40054046

BACKGROUND/OBJECTIVE: Adenomyosis is a benign uterine disorder characterized by an inflammatory and hyperestrogenic state. Its association with endometrial cancer (EC) remains controversial. This study aimed to investigate the correlation b…

2025
doi:10.1016/j.ygyno.2025.04.516 ·PMID:40222070

Objective(s)We aimed to assess the feasibility and effectiveness of a remotely delivered, group-based lifestyle modification intervention (LMI) for women with gynecologic cancer and overweight or obesity in a real-world clinic.MethodsA six-…

2025
doi:10.1016/j.ygyno.2025.05.013 ·PMID:40482607

ObjectiveMany epithelial ovarian cancer (EOC) risk factors relate to sex hormones. The association between these factors and the expression of androgen receptor (AR), estrogen receptor-α (ER), and progesterone receptor (PR) in tumors is unk…

article 2025
doi:10.1016/j.ygyno.2025.05.008 ·PMID:40499207

OBJECTIVE: Previous results on the association between statin use and risk of ovarian cancer (OC) are inconsistent, warranting further investigation. This study aims to examine the association between statin use and risk of OC in a large st…

2024
doi:10.1016/j.ygyno.2024.10.008 ·PMID:39396406

ObjectiveTo evaluate the disease course of patients with low grade endometrial stromal sarcoma (LG-ESS) and compare oncologic outcomes associated with hormonal therapy in primary and recurrent disease.MethodsThis is a retrospective study of…

other 2024
doi:10.1016/j.ygyno.2024.01.049 ·PMID:38335900

INTRODUCTION: It is unclear if sentinel node (SLN) mapping can replace pelvic- (PLD) and paraaortic lymphadenectomy (PALD) for high-risk endometrial cancer (EC). A diagnostically safe surgical algorithm, taking failed mapping cases into acc…

2024
doi:10.1016/j.ygyno.2024.07.690 ·PMID:39128337

BackgroundIndividuals with germline BRCA1 and BRCA2 pathogenic variants (BRCA carriers) are at high risk of developing high grade serous ovarian carcinoma (HGSC). HGSC is predominantly driven by TP53 mutations, but mutations in this gene ar…

2024
doi:10.1016/j.ygyno.2024.01.015 ·PMID:38246044

ObjectivesMesonephric (MA) and mesonephric-like (MLA) adenocarcinomas are rare cancers, and data on clinical behavior and response to therapy are limited. We sought to report molecular features, treatment, and outcomes of MA/MLA from a sing…

2024
doi:10.1016/j.ygyno.2024.08.010 ·PMID:39173565

ObjectiveHigh-grade (HGOC) and low-grade ovarian carcinoma (LGOC) are distinct malignancies with different biological features, treatment paradigms, and life expectancies. However, differences in quality of life (QOL), sleep, and depressive…

2024
doi:10.1016/j.ygyno.2024.08.008 ·PMID:39180961

ObjectiveTo determine whether a multimodal assay combining serum microRNA with protein biomarkers and metadata improves triage assessment of an adnexal mass.MethodsSerum samples from 468 training subjects (191 cancer cases and 277 benign ad…

article 2023
doi:10.1016/j.ygyno.2023.03.020 ·PMID:37121178

OBJECTIVE: To demonstrate that shared antibody responses in endometriosis and endometriosis-associated ovarian cancer spontaneously antagonize malignant progression and can be leveraged to develop future immunotherapies. METHODS: B cells f…

other 2023
doi:10.1016/j.ygyno.2023.06.021 ·PMID:37418832

OBJECTIVE: Gynecologic cancers are traditionally managed according to their presumed site of origin, without regard to the underlying histologic subtype. Clear cell histology is associated with chemotherapy refractoriness and poor survival.…

article 2023
doi:10.1016/j.ygyno.2023.06.579 ·PMID:37478617

OBJECTIVES: To evaluate clinical, laboratory, and radiological variables from preoperative contrast-enhanced computed tomography (CECT) for their ability to distinguish ovarian clear cell carcinoma (OCCC) from non-OCCC and to develop a nomo…

2023
doi:10.1016/j.ygyno.2023.10.013 ·PMID:37992548

ObjectiveTo assess the impact of short-term postoperative complications on oncologic outcomes for patients with epithelial ovarian cancer undergoing primary cytoreductive surgery (PCS) or interval cytoreductive surgery (ICS) with intestinal…

other 2023
doi:10.1016/j.ygyno.2022.10.018 ·PMID:36401943

OBJECTIVE: The presence of macroscopic residual disease after primary cytoreductive surgery (PCS) is an important factor influencing survival for patients with high-grade serous ovarian cancer (HGSC). More research is needed to identify fac…

other 2023
doi:10.1016/j.ygyno.2023.11.007 ·PMID:37980769

OBJECTIVE: Sistematic pelvic and para-aortic lymphadenectomy is part of the staging surgery for early-stage epithelial ovarian cancer, with no therapeutic value. The Mapping Sentinel Lymph Nodes In Early-Stage Ovarian Cancer (MELISA) trial …

other 2023
doi:10.1016/j.ygyno.2023.02.013 ·PMID:36893488

OBJECTIVE: The SENTIREC-endo study aims to investigate risks and benefits of a national protocolled adoption of sentinel lymph node (SLN) mapping in women with early-stage low-grade endometrial cancer (EC) with low- (LR) and intermediate-ri…

2022
doi:10.1016/j.ygyno.2022.02.021 ·PMID:35277280

ObjectiveBlack women suffer a higher mortality from endometrial cancer (EC) than White women. Potential biological causes for this disparity include a higher prevalence of obesity and more lethal histologic/molecular subtypes. We hypothesiz…

article 2022
doi:10.1016/j.ygyno.2022.06.021 ·PMID:36357191

OBJECTIVE: The risk of developing endometrial hyperplasia after diagnosis of endometriosis has not been determined. Moreover, the risk of endometrial cancer associated with endometriosis is unclear. This nationwide population-based study in…

other 2022
doi:10.1016/j.ygyno.2022.03.016 ·PMID:35370008

BACKGROUND: Clear cell and endometrioid ovarian carcinomas (OCC and OEC, respectively) have a presumed origin in endometriosis and share molecular alterations with each other and with their endometrial counterparts. The Cancer Genome Atlas …